I've written several bullish articles about Navidea Biopharmaceuticals (NAVB) before, but this is the first time that I will undertake a true valuation for their business rather than focusing on a qualitative assessment and stock price action. I believe that shares of Navidea are significantly undervalued at current levels and the stock presents an excellent risk/reward profile.
Crede Comes To The Table
On September 24, Navidea announced the direct sale of about 10.5 M shares to Crede at a price of $2.84 per share, the closing market price of the previous day. This deal was benign to shareholders compared to most capital raising by biotech companies; however, the market reacted extremely and slammed the stock. It is...
Only subscribers can access this article, which is part of the PRO research library covering 3,594 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: